GH Research PLC (GHRS) News
Follow GH Research PLC (GHRS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Form SCHEDULE 13G/A GH Research PLC Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:17 PM UTC
L
FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace
By Puyaan Singh and Kamal ChoudhuryThe U.S. FDA is holding a public hearing on Monday to gather feedback on the potential therapeutic use of psychedelic drugs, the latest step in a months-long push by President Donald Tr
REGULATION | Sep 14, 2026, 07:30 PM UTC
L
GHRS - GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
GHRS - GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 06, 2026, 11:02 AM UTC
L
GHRS Initiated Overweight W/$44.00 PT at Wells Fargo
GHRS Initiated Overweight W/$44.00 PT at Wells Fargo
EQUITY | Jul 27, 2026, 12:08 PM UTC
L
Peer GHRS +14% premarket after ATAI M&A headlines
Peer GHRS +14% premarket after ATAI M&A headlines
MNA | Jul 16, 2026, 11:15 AM UTC
H
FDA announces availability of final guidance for psychedelic drug research
The agency said,...
EARNINGS | Jul 15, 2026, 03:12 PM UTC
H
Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors
Jefferies notes that on...
EQUITY | Jul 13, 2026, 05:12 PM UTC
H
CMPS: Depression Drug 86% Through Phase 3
CMPS' breakthrough-designated depression drug is 86% through its Phase 3 with topline data due this year
EQUITY | Jun 26, 2026, 01:31 PM UTC